Roche and Genentech: Top 10 deals of 2009

Who: Roche
With: Genentech
What: $46.8B buyout

Summary: Genentech became a member of the Roche family last March. Although the two units are moving along in their integration process, the courtship wasn't without some wrangling. A Genentech special committee had rebuffed an earlier offer from Roche to acquire shares that the Swiss drugmaker didn't already own for $89 a share. However, the parties reached a "friendly agreement," through which Roche would pay $95 a share-or $46.8 billion. And Genentech moniker won't be going away--in October, the parties announced that all Roche meds will be rebranded for the U.S. market. But there have been layoffs. For example, 302 people were let go from the Roche Palo Alto between July and December, according to paperwork filed with California officials.